
    
      The primary objective of this study is to determine the maximum tolerated dose of TPI 287 for
      phase II clinical trials.

      The secondary objectives of the study are:

        -  To determine the safety of TPI 287

        -  To determine antitumor activity of TPI 287

        -  To determine the pharmacokinetic profile of TPI 287

        -  To determine the pharmacodynamic profile of TPI 287
    
  